Screener
CRISPR Therapeutics CRSP Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
| Line item | As of / March 31, 2026 | As of / December 31, 2025 |
|---|---|---|
| Prepaid expenses and other current assets | 6,577 | 9,843 |
| Total current assets | 2,448,362 | 1,985,671 |
| Property and equipment, net | 112,175 | 115,851 |
| Restricted cash | 7,629 | 7,629 |
| Operating lease assets | 128,671 | 131,724 |
| Other non-current assets | 28,983 | 24,368 |
| Total assets | $2,725,820 | $2,265,243 |
| Liabilities and shareholders’ equity |
Item 1. Financial Statements
FAQ
- What is CRISPR Therapeutics's restricted cash?
- CRISPR Therapeutics (CRSP) reported restricted cash of $7.63M in Q1 2026.
- How has CRISPR Therapeutics's restricted cash changed year-over-year?
- CRISPR Therapeutics's restricted cash decreased by 4.7% year-over-year, from $8.01M to $7.63M.
- What is the long-term trend for CRISPR Therapeutics's restricted cash?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's restricted cash has grown at a -14.7% compound annual growth rate (CAGR), from $16.85M to $7.63M.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about CRISPR Therapeutics's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude